The Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27715, USA.
Am Heart J. 2010 Jan;159(1):141-7. doi: 10.1016/j.ahj.2009.10.035.
Despite advances in treatment of cardiogenic shock (CS), the incidence of this serious complication of acute ST-elevation myocardial infarction (STEMI) has stayed relatively constant, and rates of mortality, although somewhat improved in recent decades, remain dauntingly high. Although both percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are used in patients with CS with multivessel coronary disease, the optimal revascularization strategy in this setting remains unknown.
We conducted a literature search and review of English language publications on CS in multiple online medical databases. Studies were included if they were (1) randomized controlled trials or observational cohort studies, (2) single-center or multicenter reports, (3) prospective or retrospective studies, and (4) contained information on PCI and CABG. Non-English language studies were excluded.
Our search retrieved no published findings from randomized clinical trials, and only 4 observational reports evaluating PCI versus CABG. Our review of the limited available data suggests similar mortality rates with CABG and PCI in patients with STEMI and multivessel coronary disease complicated by CS.
Limited data from observational studies in patients with CS and multivessel disease suggest that CABG should be considered a complementary reperfusion strategy to PCI and may be preferred, especially when complete revascularization with PCI is not possible. Our data highlight the need for large randomized trials to further evaluate the relative benefit of PCI versus CABG in patients with multivessel coronary disease and CS using contemporary surgical and percutaneous techniques.
尽管在治疗心源性休克(CS)方面取得了进展,但急性 ST 段抬高型心肌梗死(STEMI)这一严重并发症的发生率仍然相对稳定,尽管近几十年来死亡率有所改善,但仍然高得惊人。尽管经皮冠状动脉介入治疗(PCI)和冠状动脉旁路移植术(CABG)都用于多支血管病变的 CS 患者,但在这种情况下,最佳的血运重建策略仍不清楚。
我们在多个在线医学数据库中进行了文献检索和 CS 的英文文献综述。如果研究符合以下条件,则被纳入:(1)随机对照试验或观察性队列研究;(2)单中心或多中心报告;(3)前瞻性或回顾性研究;(4)包含 PCI 和 CABG 的信息。不包括非英文语言的研究。
我们的检索未发现来自随机临床试验的已发表结果,只有 4 项关于 PCI 与 CABG 的观察性报告。我们对有限的可用数据的回顾表明,在 STEMI 和多支血管疾病并发 CS 的患者中,CABG 和 PCI 的死亡率相似。
来自 CS 和多支血管病变患者的观察性研究的数据有限,表明 CABG 应被视为 PCI 的补充再灌注策略,尤其是在 PCI 无法实现完全血运重建时,可能更具优势。我们的数据强调需要进行大型随机试验,以进一步评估在使用当代外科和经皮技术治疗多支血管疾病和 CS 的患者中,PCI 与 CABG 的相对益处。